<DOC>
	<DOCNO>NCT00087464</DOCNO>
	<brief_summary>Short-term therapy may reduce amount HIV blood adult recently infect HIV . The purpose study see whether good people take short course anti-HIV drug first infect well wait HIV infection cause health problem take anti-HIV drug .</brief_summary>
	<brief_title>Three Month Course Anti-HIV Medications People Recently Infected With HIV</brief_title>
	<detailed_description>Limited access HIV treatment major problem many part world . If well tolerate anti-HIV regimen convenient once-daily dose effective reduce viral load people recent early HIV infection , regimen could use globally control HIV . This study determine effectiveness three-month antiretroviral regimen reduce viral load HIV infect adult recently infect recently seroconverted . This study recruit participant Alabama Tennessee United States Lusaka , Zambia . Participants study must also enrol AIEDRP CORE01 study . Participants study divide Early Acute group . Participants Early group people recently seroconverted ; participant Acute group people primary HIV infection . All participant choose receive once-daily dose regimen emtricitabine , nevirapine , tenofovir disoproxil fumarate . Didanosine , efavirenz , stavudine may substitute drug regimen investigator 's discretion . Participants take three-drug regimen 90 day . If participant 's CD4 count high 350 cells/mm3 Day 90 , participant stop therapy . If participant 's CD4 count 350 cells/mm3 low Day 90 , participant 's CD4 count drop 350 cells/mm3 low therapy stop , participant receive additional 30 day therapy . This therapy strategy may repeat necessary Day 180 . All participant take three-drug regimen follow , regardless whether take regimen beyond Day 90 . In addition AIEDRP CORE01 's study visit , 7 additional study visit occur pretreatment , Day 3 , Weeks 1 , 3 , 8 , 16 , 20 . Blood collection occur study visit . Data study participant compare data historical cohort previously identify HIV infect adult acute early infection receive treatment follow prospectively .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Acute early HIV infection , determine NIH Acute Infection Early Disease Research Program ( AIEDRP ) definition Coenrolled AIEDRP CORE01 trial Willing use acceptable method contraception Any severe medical illness , opinion investigator , interfere ability adhere therapy result make therapy risky patient Significant psychiatric illness ongoing substance abuse , opinion investigator , compromise ability patient follow study procedure safely consistently Hepatitis B C infection AND liver enzymes Grade 2 great OR evidence history severe hepatitis cirrhosis Creatinine clearance le 50 ml/min Received one month prior antiretroviral therapy . Women receive shortterm dose nevirapine prevent mothertochild transmission childbirth exclude meet study requirement . They give nevirapine part initial study regimen resistance test do confirm nevirapine resistance . Coenrolled HIV treatment investigational drug trial Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Acute Infection</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Treatment Interruption</keyword>
</DOC>